Lymphoma, B-Cell, Marginal Zone Clinical Trial
Official title:
Hepatitis B Virus Reactivation in Patients With Marginal Zone B-cell Lymphoma After Rituximab Containing Treatment: Consortium for Improving Survival of Lymphoma (CISL) Marginal Zone Lymphoma Cohort Study (MARCO)
Marginal zone lymphoma is a rare of subtype of Non-Hodgkin Lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want to make prospective MZL patients' cohort for several observation study
Marginal zone lymphoma (MZL) is a distinct subgroup of non-Hodgkin's lymphoma (NHL), which is
typically characterized by an indolent clinical course and long survival duration. MZL is
responsible for approximately 7~8% of all NHL. In Korea, MZL accounts for 21% of all B-cell
lymphoma and is the second most frequent histologic subtype following diffuse large B-cell
lymphoma. Annually, an estimated 500 patients are newly diagnosed with MZL. According to the
previous large-scale analyses, MZL is usually a quiet indolent malignancy, which generally
presents with limited stage of disease. Localized disease may be controlled with local
treatment, and a high response rate can be achieved. Advanced MZL is associated with less
favorable survival, and appears to be incurable with the currently available therapy.
Transformation to large cell aggressive lymphoma may occur in the first recurrence or in
subsequent relapses.
Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want
to make prospective MZL patients' cohort for several observation study especially related
with Rituximab use (ex, Hepatitis B virus (HBV) reactivation)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03646422 -
AEDV Registry of Primary Cutaneous Lymphoma
|
||
Active, not recruiting |
NCT04849416 -
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
|
Phase 2 | |
Completed |
NCT02257242 -
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
|
Phase 1 | |
Withdrawn |
NCT01263418 -
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
|
Phase 2 | |
Terminated |
NCT03093831 -
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
|
Phase 2 |